Medicines in Morocco: therapeutic promise, regulatory risk and patient safety
A box of tablets may look like an ordinary consumer product. Legally, it is anything but ordinary. Before a medicine can be manufactured, imported, distributed or supplied in Morocco, its quality, safety and therapeutic value must pass through a tightly controlled regulatory process. Once the product reaches the market, surveillance does not stop. Adverse reactions must be collected, safety signals assessed and, where necessary, batches recalled or the marketing authorisation suspended.
This subject has returned to the centre of public debate following press reports, including coverage by Medias24, about reforms affecting pharmaceutical regulation, pharmacovigilance and market surveillance. That debate must now be read alongside a decisive institutional development: Law No. 10-22 created the Moroccan Agency for Medicines and Health Products, commonly referred to by its French acronym, AMMPS. The reform is therefore no longer merely a proposal to create an agency. The real questions concern its implementation, the transfer of functions historically performed by the Directorate of Medicines and Pharmacy, and the practical changes experienced by operators.
Consider a composite but very realistic Casablanca scenario drawn from recurring compliance files. During an inspection, health and law-enforcement officers find injectable products in a medical practice. They were purchased abroad, transported in personal luggage and stored without documented temperature monitoring. The practitioner has prescriptions and believes the products are clinically useful. What is missing, however, is just as significant: no Moroccan marketing authorisation, no exceptional import approval, no customs traceability and no evidence that the cold chain was maintained.
The case is not transformed into a lawful operation simply because the medicine is authorised in France, Spain or the United States. A foreign approval does not automatically constitute an autorisation de mise sur le marché, or AMM, in Morocco. Depending on the facts, the doctor, importer, supplier, pharmacist or company director may face seizure of the products, administrative measures, professional discipline, civil liability and criminal prosecution.
This article explains the Moroccan drug AMM procedure, the applicable pharmacovigilance rules, the legal consequences of unauthorised imports, the distinction between suspension and withdrawal, and the remedies open to companies and injured patients. It also corrects several claims frequently repeated online. In pharmaceutical law, an approximate article number or an assumed “three-month personal-use exemption” can be a costly mistake.
1. The legal foundation: Law No. 17-04 on medicines and pharmacy
1.1 A public-health code, not a simple business licensing statute
The central text is Law No. 17-04 establishing the Code of Medicines and Pharmacy, promulgated by Dahir No. 1-06-151 of 30 Shawwal 1427, corresponding to 22 November 2006, and published in Official Gazette No. 5480 of 7 December 2006. The Code governs medicines, pharmaceutical establishments, pharmacists, manufacture, importation, distribution, dispensing, inspections and offences.
Article 1 of Law No. 17-04 contains the core statutory definition of a medicine. In substance, it covers substances or compositions presented as having curative or preventive properties, as well as products that may be administered to establish a medical diagnosis or to restore, correct or modify physiological functions through a pharmacological, immunological or metabolic action. This definition matters. Calling a product a “food supplement”, “natural injection” or “wellness preparation” does not prevent reclassification when its presentation, composition or claimed function places it within the legal definition of a medicine.
The regulatory principle: the legal classification depends on what the product is, what it contains, how it works and how it is presented—not merely on the commercial description chosen by the seller.
Article 7 of Law No. 17-04 establishes the fundamental AMM requirement for industrially manufactured medicines before marketing or distribution, whether for payment or free of charge, subject to the exceptions and special procedures provided by law. This is the legal heart of the Moroccan marketing-authorisation system.
The implementing framework includes Decree No. 2-14-841 concerning marketing authorisation for medicines for human use. The decree specifies procedural and technical elements governing applications, evaluation, amendments, renewal and post-authorisation measures. Ministerial orders, administrative forms, technical guidelines and published filing requirements complete the framework. Operators should always consult the consolidated texts and the current instructions of the competent authority; relying on a regulatory checklist downloaded several years earlier is unsafe.
1.2 The competent authorities: from the DMP to the Moroccan Medicines Agency
Historically, applications were handled through the Direction du Médicament et de la Pharmacie, generally abbreviated DMP or sometimes DMPP in professional usage, under the Ministry of Health and Social Protection. Its functions included pharmaceutical evaluation, establishment oversight, inspection support, authorisation processing and aspects of market surveillance.
Law No. 10-22 introduced a new institutional architecture by creating the Moroccan Agency for Medicines and Health Products. The Agency is intended to provide a more specialised and operational structure for scientific evaluation, authorisations, vigilance and control. For companies, however, a statutory transfer of competence does not instantly resolve every administrative difficulty. Transitional arrangements, implementing measures, electronic systems and the actual transfer of files determine where and how a submission is handled at a given date.
Concretely, applicants should verify the currently competent filing channel before submission. They should not assume that an old DMP form, bank reference or paper submission route remains valid merely because it was accepted for an earlier product.
1.3 International standards and Moroccan legal requirements
Morocco increasingly uses documentation and evaluation practices influenced by the Common Technical Document, World Health Organization guidance and International Council for Harmonisation standards. For multinational laboratories, this facilitates reuse of scientific material. It does not eliminate Moroccan requirements.
Local labelling, Arabic and French documentation, the identity of the Moroccan operator, manufacturer authorisations, certificates of pharmaceutical product, good manufacturing practice evidence, pricing steps and local pharmacovigilance arrangements may all require specific treatment. An EU dossier cannot simply be uploaded unchanged and expected to pass validation.
2. The Moroccan marketing authorisation procedure
2.1 Who may apply?
An AMM application must be connected to an operator legally entitled to assume the relevant pharmaceutical responsibilities. Depending on the proposed model, this may involve a Moroccan pharmaceutical industrial establishment, an authorised importer or a locally established entity working with a foreign manufacturer. The applicant must also demonstrate that the manufacturing and control sites comply with the applicable pharmaceutical standards.
This point should be addressed before commercial negotiations are finalised. Foreign manufacturers sometimes sign an exclusive distribution agreement and only later discover that the chosen distributor does not possess the pharmaceutical status, facilities or technical organisation needed for the intended operation. A distribution contract cannot replace an establishment authorisation.
The allocation of responsibilities must be explicit: Who is the AMM holder? Who releases batches? Who communicates with the authority? Who maintains the pharmacovigilance system? Who pays for recalls and destruction? A Moroccan commercial-law lawyer should review those issues together with regulatory counsel, because a commercially attractive contract may still be unusable under pharmaceutical law.
2.2 What does an AMM dossier contain?
The dossier is generally organised on a CTD-style basis. Its administrative component identifies the applicant, manufacturer, sites, authorisations and proposed product information. The quality section describes the active substance, excipients, manufacturing process, process validation, analytical methods, specifications, container-closure system, stability data and proposed shelf life.
Non-clinical and clinical modules must support safety and efficacy. For a generic medicine, the applicant will usually rely on the reference product and submit evidence of pharmaceutical equivalence and, where required, bioequivalence. A waiver cannot be assumed merely because the active ingredient is old. The dosage form, solubility, therapeutic index and applicable guidance affect the evidence required.
The practical validation package commonly includes:
- corporate and pharmaceutical-establishment documents;
- manufacturing licences and good manufacturing practice evidence;
- a certificate of pharmaceutical product where applicable;
- quality, stability and batch-control data;
- non-clinical and clinical reports or justified bibliographic reliance;
- bioequivalence data for relevant generic applications;
- the summary of product characteristics, labelling and patient leaflet;
- samples, reference standards or analytical material when requested;
- the proposed pharmacovigilance organisation and local safety contact;
- proof of payment of the applicable regulatory fees.
Classic error: treating administrative validation as a minor preliminary step. If powers of attorney, legalised documents, certificates, translations or manufacturer details do not match across the dossier, substantive scientific review may not begin. The official review clock may be suspended while questions are answered; it does not necessarily “restart from zero” in every case, but an invalid or materially incomplete application may require correction or refiling.
2.3 The 210-day period and the reality of regulatory time
The figure most often cited for substantive examination is 210 days, subject to the procedural rules and to clock stops while the applicant supplies additional information. It should not be marketed to investors as a guaranteed seven-month route to sales. Validation, scientific questions, inspections, laboratory testing, pricing and administrative completion may extend the overall timeline.
In files handled during the 2023-2025 period, market participants frequently reported total timelines of 18 to 36 months for innovative or complex products. A strong generic dossier with clear bioequivalence evidence may progress more quickly, sometimes in roughly 12 to 15 months, but that is a practical observation, not a legally enforceable promise.
One recurring type of file involves a foreign laboratory that submits through a local partner, receives several rounds of technical questions and then waits without a clear consolidated timetable. By the third year, the commercial assumptions behind the distribution agreement have changed. At that stage, counsel should first obtain a documented procedural status, identify unanswered requests and send a formal demand to the competent authority. Administrative litigation may be considered where a legally reviewable express or implied decision exists, but a court does not substitute itself for the scientific evaluator and issue the AMM.
2.4 Generic, essential and exceptional products
Generic applications benefit from reliance on an authorised reference medicine, but “simplified” does not mean superficial. Quality and bioequivalence remain central. Deficiencies in the comparator choice, study population, analytical method or statistical analysis can delay or defeat an application.
Public-health emergencies, shortages and named-patient needs may justify special import or supply mechanisms. These mechanisms are exceptional and documented. They are not a back door for launching an unregistered medicine commercially. An authorisation covering a defined quantity for a hospital or patient does not automatically permit general distribution to pharmacies.
2.5 Regulatory costs and hidden compliance expenditure
Official fees must be checked against the tariff applicable on the date of filing. Figures of MAD 5,000 to MAD 15,000 are sometimes quoted for certain filing steps, but they should not be treated as a universal statutory tariff. Product category, application type, analysis and subsequent variations may affect the amount.
The larger expense is dossier preparation. Depending on complexity, local regulatory consulting and legal coordination may range from approximately MAD 30,000 to MAD 150,000, excluding bioequivalence studies, translations, stability work, laboratory analysis, GMP remediation and foreign-document legalisation. For a biologic or technologically complex medicine, the total is far higher.
3. Pharmacovigilance under Moroccan regulation
3.1 What pharmacovigilance actually means
Pharmacovigilance is the organised detection, assessment, understanding and prevention of adverse effects and other medicine-related risks. It begins before approval but becomes especially important after launch, when the product is used by larger and more diverse populations than those enrolled in clinical trials.
A valid AMM is not a declaration that the medicine is risk-free. It means that, for the authorised uses and conditions, the expected benefits were considered to outweigh the known and reasonably assessed risks. That balance may change when new data emerge.
3.2 Obligations of the AMM holder
The AMM holder must maintain an effective system capable of receiving, documenting, medically assessing and transmitting safety information. In practical terms, a compliant operator should appoint a qualified pharmacovigilance contact, maintain written procedures, train staff, reconcile complaints with safety reports and preserve an auditable record of decisions.
Serious suspected adverse reactions are generally handled on an expedited basis, with 15 calendar days commonly applied in pharmacovigilance practice and authority requirements. Other reports and aggregate data follow the applicable reporting schedule and the conditions imposed on the product. Companies should not rely on a generic claim that every non-serious case has a universal “90-day statutory deadline” under Law No. 17-04; the precise obligation depends on the applicable rules, guidelines, AMM conditions and authority requests.
Periodic safety update reports, risk-management measures, literature monitoring and signal assessment may also be required. When a new serious risk is identified, the holder must not wait for the next periodic report. It should notify the authority, reassess the benefit-risk balance and propose measures such as a warning, leaflet amendment, restricted indication, batch recall or suspension.
For a medium-sized portfolio, a credible local pharmacovigilance system can cost between MAD 200,000 and MAD 500,000 per year, and more if case volumes are high or regional activities are centralised in Morocco. Outsourcing does not transfer legal accountability. The AMM holder remains responsible for oversight of its service provider.
3.3 The CAPM and adverse-effect reporting
The Centre Anti-Poison et de Pharmacovigilance du Maroc, or CAPM, plays a central role in collecting and analysing reports. Healthcare professionals can report suspected adverse reactions, medication errors, interactions and other safety concerns. Patients may also communicate suspected reactions directly, even though patient reporting remains less common than professional reporting.
Under-reporting is a genuine weakness. Doctors are busy, hospital systems are fragmented and a causal link is often uncertain. Yet uncertainty is not a reason to remain silent. A notifier reports a suspicion; the notifier is not expected to prove scientific causation before filing.
A serious event should be reported promptly when there is a reasonable suspicion of a link. Reporting does not amount to an admission of medical negligence or product defect.
The COVID-19 period exposed both the value and the limits of national safety surveillance. It increased public awareness of vaccine and medicine safety, while highlighting the need for interoperable digital reporting, faster feedback and clearer communication.
3.4 Duties of doctors, pharmacists and hospitals
Physicians should document the product name, dose, batch number where available, chronology, concomitant treatments, medical history and outcome. Pharmacists are often the first professionals to hear that a patient stopped treatment because of an unexpected reaction. Hospitals should have internal channels ensuring that serious cases reach both the relevant pharmacovigilance contact and national reporting system.
Attention, however: reporting to the manufacturer does not necessarily replace reporting through the appropriate national channel, and notifying the CAPM does not relieve the AMM holder of its own expedited-reporting duties.
4. Suspension, withdrawal, variation and recall of an AMM
4.1 Four measures that should not be confused
A variation modifies the authorised dossier, for example the manufacturing site, formulation, shelf life or product information. A batch recall removes specified lots because of a quality or safety problem. A suspension temporarily prevents marketing while a risk is assessed or deficiencies are corrected. A withdrawal or revocation ends the authorisation and ordinarily requires the product to leave the market.
Online summaries often attribute suspension and withdrawal mechanically to “Articles 21 and 22 of Law No. 17-04”. That citation should not be repeated without checking the consolidated official text and the relevant implementing decree. The lawful basis and procedure depend on the nature of the measure, the AMM conditions and the public-health powers being exercised.
Possible grounds include an unfavourable benefit-risk balance, lack of therapeutic efficacy, harmful effects, inaccurate dossier information, non-compliant manufacture, failure to perform required controls, pharmacovigilance deficiencies or failure to comply with post-authorisation conditions.
4.2 Procedure and the right to be heard
A decision affecting an AMM must be issued by the competent authority and communicated according to the applicable rules. Depending on the measure, publication, direct notification and instructions to wholesalers, hospitals and pharmacies may follow. The authority may require immediate cessation or allow a short operational period for recall. There is no universal 30-day withdrawal period.
Where immediate danger does not require urgent action, respect for defence rights and a meaningful opportunity to answer allegations are important. A company should request the inspection report, scientific grounds, identified non-conformities and the legal basis of the proposed measure. It should respond with evidence, not public-relations language.
4.3 Administrative remedies and strict deadlines
A company may submit an administrative appeal to the decision-making authority or its hierarchical superior, where available. Judicial review is governed principally by Law No. 41-90 establishing administrative courts. Under Article 23 of Law No. 41-90, an action for annulment must generally be brought within 60 days from publication or notification of the contested administrative decision, subject to the rules concerning prior administrative appeals.
The competent court is not automatically the Administrative Court of Rabat in every pharmaceutical dispute. Territorial jurisdiction depends on the defendant authority, the place where the decision was taken and the applicable procedural rules. Rabat is frequent for central administrative decisions, but jurisdiction must be analysed rather than assumed.
Under Article 24 of Law No. 41-90, an annulment action does not itself suspend execution. The administrative court may exceptionally order a stay where a specific request is made and the legal conditions are met. A laboratory facing immediate market removal should therefore consider a properly evidenced application for suspension together with the main annulment claim. A Moroccan administrative-litigation lawyer should be instructed before the 60-day period expires.
No responsible practitioner should cite an unnamed Rabat judgment as if it were settled published precedent. Moroccan pharmaceutical case law is not always readily searchable, and confidentiality often limits access. Where a judgment number, date and court cannot be verified, the case should be described as practice experience—not as a formal judicial authority.
5. Unauthorised imports, counterfeit medicines and online sales
5.1 Personal use is not a universal exemption
Patients sometimes need a medicine unavailable in Morocco. A limited personal import supported by a genuine prescription may be accepted or specially authorised, but there is no safe basis for stating that every person has an automatic statutory right to import “three months of treatment”. The medicine, quantity, controlled-substance status, transport conditions and customs circumstances all matter.
For rare diseases, urgent treatment or hospital need, the prudent route is to obtain the appropriate exceptional import authorisation before shipment. The application should identify the patient or institution, prescriber, diagnosis, medicine, quantity, foreign source and medical justification. Claims of a guaranteed 72-hour decision should also be avoided unless the authority has expressly confirmed an emergency service standard for that procedure.
Commercial importation disguised as a series of personal parcels is plainly more dangerous. A lawyer specialising in Moroccan import law can coordinate pharmaceutical, customs and contractual requirements before goods reach the border.
5.2 Criminal and administrative exposure
Manufacturing, importing, holding for unlawful supply or marketing a medicine without the required authorisation can trigger offences under Law No. 17-04, together with seizure, confiscation, closure measures and professional sanctions. The exact penalty depends on the offence charged and the applicable penalty provision.
A widely circulated claim states that Article 80 of Law No. 17-04 automatically imposes two to five years’ imprisonment and a fine of MAD 100,000 to MAD 500,000 for every sale without an AMM. Businesses should not rely on that citation: Article 80 is not a safe standalone reference for that proposition, and criminal penalties must be matched to the exact offence in the official consolidated Code. Moroccan criminal law is interpreted strictly.
Liability may extend beyond the company. Technical directors, de facto decision-makers and individuals who knowingly organise the operation may be prosecuted according to their personal participation and the relevant statutory provisions. A corporate title does not create automatic guilt, but it does not provide immunity either.
5.3 Falsified and counterfeit medicines
A falsified medicine may misrepresent its identity, composition, source or history. A counterfeit may additionally infringe a trade mark or other intellectual-property right. The same shipment can therefore generate pharmaceutical, customs, consumer-protection, intellectual-property and general criminal proceedings.
The Customs and Indirect Tax Administration may intercept suspicious goods at borders and postal facilities. Police and judicial-police officers may investigate supply networks, while health inspectors assess pharmaceutical compliance. Products arriving through informal routes from Europe, including luggage and parcel channels, present particular traceability and storage risks.
Where falsification endangers life, the legal consequences can be severe, but assertions that a particular article automatically carries ten years’ imprisonment must be verified against the charged facts and current official text. Anyone facing such allegations needs an experienced business-crime lawyer immediately.
5.4 Is online medicine sale legal in Morocco?
It is misleading to describe online medicine sales as a harmless “grey area”. Law No. 17-04 structures the pharmaceutical monopoly, authorised establishments and dispensing through pharmacies. The absence of a detailed e-pharmacy decree does not authorise a website, social-media account or foreign marketplace to bypass AMM, import and dispensing rules.
Online reservation or communication by a lawful pharmacy is not necessarily equivalent to remote sale and cross-border shipment. Prescription medicines, cold-chain products and controlled substances create additional risks. Until a specific framework clearly authorises and regulates e-pharmacy operations, operators should adopt a conservative compliance position.
6. Civil liability for medicine-related injury
6.1 The legal grounds available to patients
Morocco does not yet offer a pharmaceutical injury-compensation system equivalent to the French ONIAM. A patient generally turns to ordinary civil-liability and contractual rules in the Dahir forming the Code of Obligations and Contracts, known as the DOC.
Article 77 of the DOC addresses intentional acts causing material or moral damage. Article 78 establishes liability for damage caused by fault, including imprudence or negligence. Article 88 may be relevant to damage caused by things under a person’s custody, subject to its conditions. Article 97 concerns solidarity in specified situations involving several persons responsible for damage. Where the dispute arises from sale, the warranty against latent defects under Article 549 and following of the DOC may also be examined.
These provisions are not interchangeable. A claimant must identify the defendant’s legal role—manufacturer, AMM holder, importer, distributor, pharmacist, prescriber or hospital—and establish the elements of the chosen cause of action.
6.2 Fault, damage and causation
The patient must ordinarily prove compensable injury and a causal connection with the medicine, as well as fault where the selected basis requires it. Possible faults include defective manufacture, contamination, inadequate warnings, delayed safety reporting, improper storage, dispensing error or prescription contrary to recognised precautions.
Causation is the hardest part. The medicine may have been taken with other treatments; the underlying disease may cause similar symptoms; scientific literature may show only a statistical association. Courts therefore often need a medical expert to analyse chronology, dechallenge and rechallenge, alternative causes, dosage and known pharmacology.
A victim should preserve prescriptions, invoices, packaging, batch numbers, leaflets, laboratory results, hospital reports and proof of lost income. Remaining tablets should not be discarded. Where the condition is serious, an early medical-legal assessment may be decisive.
6.3 Jurisdiction and limitation
A civil claim may be brought before the territorially competent court of first instance, subject to procedural and jurisdictional rules. It is not always simply the court of the victim’s domicile. If a public hospital or administrative body is sued, administrative jurisdiction may need to be considered.
Article 387 of the DOC provides the general 15-year limitation period for obligations unless a special rule applies. That does not mean every pharmaceutical claim can safely wait 15 years. The legal character of the action, the defendant and special limitation rules may alter the period, while evidence deteriorates rapidly. Prompt advice from an experienced civil-liability lawyer is therefore essential.
Occasionally, unreported case summaries claim awards such as MAD 800,000 for leaflet deficiencies. Unless the court, date and judgment reference are verifiable, such figures should not be presented as jurisprudence. Moroccan courts assess proven medical costs, disability, lost earnings, assistance needs and moral harm case by case.
7. What the current reforms change
7.1 An agency has been created; implementation remains the test
The creation of the Moroccan Agency for Medicines and Health Products under Law No. 10-22 is intended to strengthen specialisation, scientific assessment, vigilance and market control. The relevant policy comparison is not whether Morocco should copy France’s ANSM or the European Medicines Agency, but whether the new institution receives sufficient expertise, digital tools, budget and decisional transparency.
The reform may shorten processing times through electronic validation, parallel review and clearer tracking. It may also initially create transitional friction as files, staff and procedures move from one structure to another. Companies should maintain a written regulatory timeline and keep proof of every submission.
7.2 Stronger post-market surveillance
A national digital reporting platform accessible to professionals and patients would improve case capture, provided reports receive meaningful feedback. Better links between pharmacovigilance, quality-defect reporting, laboratory control, customs information and hospital data are equally necessary.
For laboratories, stronger surveillance means more than purchasing software. It requires trained staff, local accountability, documented signal meetings, distributor agreements containing safety clauses and rapid recall capability. Small Moroccan manufacturers may need transition periods and shared technical solutions, but patient safety cannot be postponed indefinitely.
7.3 African harmonisation and export opportunities
Morocco has a strategic interest in African regulatory harmonisation, including initiatives connected to the African Medicines Agency and the African Continental Free Trade Area. Greater reliance and work-sharing may support Moroccan exports and reduce duplication. Recognition is not automatic, however. Each destination retains its legal requirements unless a binding or operational reliance mechanism applies.
8. Practical compliance checklist
Before launch, every pharmaceutical operator should be able to answer five questions without hesitation:
- Is the product legally classified? Borderline products should be assessed before advertising or importation.
- Is the AMM valid and consistent with the actual product? Site, formula, packaging, indication and shelf life must match the authorised dossier.
- Is the supply chain authorised? Every manufacturer, importer, wholesaler and dispensing channel must have the required legal status.
- Does pharmacovigilance work in practice? Staff must know where to send a safety complaint received by telephone, email or a sales representative.
- Can the company execute a recall immediately? Batch traceability, customer lists, communication templates and decision-making authority should already exist.
Patients and professionals should also remember a simple rule: retain evidence and report early. An adverse-effect report protects future patients even when the causal relationship remains uncertain.
Conclusion
The Moroccan pharmaceutical framework rests on three connected obligations: obtain lawful market access, maintain product quality and monitor safety throughout the medicine’s life. An AMM is not a decorative certificate, and approval abroad is not approval in Morocco. Importers must verify exceptional routes before shipment, laboratories must maintain real pharmacovigilance systems, and healthcare professionals must report serious suspected reactions.
When an AMM is suspended or withdrawn, the 60-day administrative-litigation period may become decisive. When a patient is injured, medical documentation and expert evidence are often more important than dramatic allegations. And when criminal exposure arises, every article and penalty must be checked against the official consolidated text rather than copied from an online summary.
The medicine is not a product like any other. Moroccan law recognises that fact; manufacturers, importers, pharmacists, doctors and digital sellers must recognise it too.
